A German Biotech's $6.4 Million Bet to Redefine Heart Disease Treatment

Jan de Vries · 2026-08-28

There's a new player in the European biotech scene, and it's aiming straight for the heart of a massive medical challenge. Revier Therapeutics, a startup based in Heidelberg, Germany, has just launched and secured a significant $6.4 million seed round. This isn't just another funding story—it's about a fresh approach to treating cardiometabolic diseases that affect millions. Think about conditions like heart failure and atherosclerosis. Despite all the progress in medicine, treatment options for many patients are still frustratingly limited. That's the gap Revier is trying to fill, and they've convinced a solid group of investors to back their vision. ### The Science Behind the Startup So, what's their big idea? It all centers on enzymes called HDACs, which play a role in some serious diseases. Earlier attempts to target them were a bit like using a sledgehammer—they worked but came with heavy side effects. Revier's team believes they've found a scalpel. Their focus is on a specific subclass known as class IIa HDACs. They're developing small molecule drugs, taken by mouth, designed to do something pretty clever: inhibit the bad enzymatic activity that drives disease while leaving the healthy, essential functions alone. It's about precision, not brute force. As Prof. Johannes Backs, the company's scientific founder, puts it, this selective targeting is key to being effective without the nasty side effects that plagued earlier approaches. ### The Funding and What's Next The $6.4 million seed round was led by the KHAN Technology Transfer Fund II. They weren't alone—High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg all joined in. It's a vote of confidence from the region's tech and investment community. Michael Hamacher from KHAN highlighted the team's deep expertise and the unique potential of their strategy to actually modify the course of disease, not just manage symptoms. So, what's the plan for the cash? Revier is moving full speed ahead on two main programs: - Their lead program targeting heart failure with preserved ejection fraction (HFpEF). - A second program for atherosclerotic cardiovascular disease (ASCVD). The money will fuel this preclinical work and help them build out the operational and clinical teams needed to eventually bring these therapies to patients. ### Why This Matters for the Ecosystem Look, launching a biotech company is never easy. Doing it with a novel approach to some of the world's biggest health problems is even harder. Revier's launch and funding signal something important. It shows that European investors are still willing to back deep, ambitious science coming out of strong academic hubs like Heidelberg. For professionals watching the EU startup scene, it's a case study in translating complex research into a viable company. It's about more than just a therapy; it's about building a team, securing capital, and navigating the long road from the lab to the clinic. This German biotech's first steps are worth watching closely.